Reporting guideline provided for? (i.e. exactly what the authors state in the paper)
Tumour marker prognostic studies
Full bibliographic reference
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.
Language
English
PubMed ID
Relevant URLs (full-text if available)
Download the REMARK checklist (Word) for tumour marker prognostic studies.
Explanation and elaboration papers
Abridged explanation and elaboration
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018. PMID: 29873743
Detailed explanation and elaboration
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
BMC Med. 2012;10:51. PMID: 22642691
PLoS Med. 9(5):e1001216. Link to full-text
Reporting guideline acronym
REMARK
Study design
Diagnostic and prognostic studies, Observational studies
Clinical area
Genetics, Oncology
Applies to the whole report or to individual sections of the report?
Whole report
Other relevant research (i.e. research regarding the guideline’s effectiveness usability, impact etc.)
REMARK profile to aid structured reporting
Sauerbrei W, Haeussler T, Balmford J, Huebner M. Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Med. 2022;20(1):184. PMID: 35546237
Record last updated on
May 16, 2022
Training
The UK EQUATOR Centre runs training on how to write using reporting guidelines.